GlassScriptPhysician profile
Dorothea Jacobsen
NPI 1437116084
$3,216.43
in general payments reported to CMS, 2019-2025
31 companies · $596 in 2025
The $596 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $214 · 2021: $542 · 2022: $576 · 2023: $467 · 2024: $678 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,136.70 | 2021-2025 | |
| Novo Nordisk INC | $421.76 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $235.40 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $177.63 | 2021-2024 | Mounjaro |
| Astellas Pharma US INC | $121.63 | 2024-2025 | Veozah |
| Pfizer INC. | $116.43 | 2019-2023 | |
| Allergan, INC. | $94.87 | 2019-2020 | |
| Exact Sciences Corporation | $84.17 | 2024-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.97 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $65.72 | 2020-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $65.19 | 2022 | |
| Merck Sharp & Dohme LLC | $63.83 | 2021-2024 | Gardasil 9, Vaxneuvance, Capvaxive |
| Actelion Pharmaceuticals US, INC. | $57.26 | 2024-2025 | Opsumit, Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $49.95 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.14 | 2025 | Caplyta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $46.00 | 2020-2025 | Spravato |
| Abbott Laboratories | $44.89 | 2025 | Freestyle Libre 3 |
| Medtronic, INC. | $42.30 | 2023-2025 | Symplicity G3, Intellis Adaptivestim |
| Kowa Pharmaceuticals America, INC. | $40.08 | 2021-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.89 | 2019-2020 | |
| Amgen INC. | $28.40 | 2023-2025 | Evenity, Prolia |
| Sanofi Pasteur INC. | $26.39 | 2019-2020 | |
| Seqirus USA INC | $20.28 | 2025 | Fluad, Flucelvax |
| Nestle Healthcare Nutrition INC. | $19.46 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.57 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.06 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.07 | 2023 | Rexulti |
| Corcept Therapeutics | $13.94 | 2025 | Korlym |
| Adlon Therapeutics L.P. | $13.14 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.63 | 2022 | |
| Mayne Pharma Commercial LLC | $9.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorothea Jacobsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.